Double BMT recipient to ride in New Year's Day float

For the first time, a recipient of a bone marrow transplant will ride on the Donate Life Rose Parade Float in Pasadena on New Year's Day 2011.

Victor Villalobos is a California resident whose diagnosis of non-Hodgkin lymphoma led him to undergo an autologous BMT when he was not yet 20 years old. Unfortunately it failed, leading Villalobos to undergo a second BMT, this time the riskier allogenic transplant.

"I am so excited I've been telling everyone I know," said the young man. "Sometimes I forget who I've told and I tell them again."

Villalobos' presence on the float, dubbed "Seize The Day", is sponsored by Loma Linda University Medical Center Transplantation Institute. He'll join 29 other patients who have undergone transplants involving several different organs. The point of the float is to draw attention to donor programs and encourage people to become donors of tissue, organs, and stem cells.

Contra Costa Times

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap